top of page


From Possibility to Clinical Imperative:

Why payers must facilitate the use of technology that was built specifically for precision medicine in oncology care.



It's clear that legacy UR/UM technologies and traditional processes like prior authorization were not designed to scale into the rapidly growing and complex age of precision oncology. 

What's needed is a centralized, end-to-end platform for precision medicine testing and treatment selection that gives payers the assurance that they are reimbursing for:

  • precisely the right tests for exact biomarker and from the right lab; and 

  • the most appropriate treatment for their patient member, every time. 

Download the whitepaper to learn why it is critical for payers and providers to standardize the use of precision oncology and the ways that leading organizations are implementing decision-support technologies to ensure cancer patients have the opportunity for the best outcome.

See Trapelo for Health Plans
Request a demo to see how the first-of-its-kind precision medicine platform, Trapelo, can deliver a 7:1 ROI, improve the speed and accuracy with which patients are matched to the exact right therapy, and truly create a value-based system for precision oncology care.


Ravi Salgia (Tiff)_Crop.png

Ravi Salgia, M.D., Ph.D.

Professor and Chair, Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center


Janine Morales., Ph.D.

Senior Director Clinical Knowledge Systems,Trapelo Health

How can we resolve the complexities of using precision medicine for cancer care?

Trapelo knows.

bottom of page